Boston Scientific Continues to Be Relentless with M & amp;A

Boston Scientific is set to acquire Cryterion Medical, a company developing single-shot cryoablation platform for the treatment of atrial fibrillation (AF), for about $202 million in up-front cash. The price is for the 65% remaining stake in the Carlsbad, CA-based company, not already owned by Boston Scientific. The Cryterion Medical cryoablation platform uses cryothermal energy to interrupt the irregular electrical signals that can cause AF. Developed with a next-generation balloon catheter, advanced mapping catheter, steerable sheath and enhanced console, the system is designed to streamline overall procedural workflow, enhance maneuverability and improve positioning in challenging anatomy. Performance of the cryoablation system from Cryterion Medical is being investigated in a clinical study in Europe. Clinical evidence from this study will be included in a regulatory submission for CE Mark, expected in early 2019. The company will also pursue regulatory approval in the U.S. and plans to submit an investigational device exemption (IDE) application to FDA with patient enrollment expected to begin in 2019. "The acquisition of Cryterion Medical enhances our AF ablation procedure offerings, allowing physicians to select a therapeutic option based on clinical preference and specific patient needs," Kenneth Stein, M.D., senior vice president and chief medical officer, Rhythm Management and Global Health Policy, Boston Scientific, said in a release. "We are committed to providing...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news